ArticleCureus2024
Lung Disease in Sjögren's Syndrome: Insights From a Reference Center's Population.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Sjögren's syndrome (SS) is a chronic systemic autoimmune disorder characterized by lymphocytic infiltration of the exocrine glands. Although primarily affecting these glands, the syndrome can also involve several organs. Interstitial lung disease is one of the most severe complications associated with SS. Objectives This study aims to analyze the characteristics of lung involvement in patients with primary SS from a reference medical center's population. Methods Retrospective, longitudinal study of primary SS patients diagnosed until December 2022. Clinical and laboratory data were collected and subjected to statistical analysis using SPSS®. A 95% confidence interval was considered, with statistical significance set at p<0.05. Results A total of 126 patients were included, 95.2% of whom were females, with a mean age at diagnosis of 50 years. The median EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) at diagnosis was 3, which decreased to 1 at the last evaluation. Based on the ESSDAI lung domain, nine patients presented with lung disease at diagnosis. This number increased to 18 by the last assessment. Thoracic tomography showed lung disease in 30 patients, with bronchiectasis being the most common finding. Ten patients presented with interstitial lung disease. Pulmonary function tests were abnormal in 18 patients, and the diffusing capacity of the lungs for carbon monoxide was reduced in 32. Patients with lung disease were more likely to experience a dry cough (p<0.01), have positive SSA antibodies (p<0.05), antinuclear antibody (ANA) >1/320 (p<0.01), positive rheumatoid factor (p<0.01), and low C4-complement during follow-up (p<0.05). Conclusions The authors found an association between clinical and analytical findings and the presence of lung disease in SS patients. Further research is essential to identify optimal predictors of SS-associated lung disease, facilitating early diagnosis and intervention for both SS and its related lung complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.